Darwin Global Management: Stock Portfolio, Performance and Latest Trades
13F portfolio value
$3.8B
5 holdings at Q2 2026
Get an email when Darwin Global Management files a new 13F report
Free, no account needed. Unsubscribe with one click.
Darwin Global Management's portfolio
As of Q2 2026, filed August 14, 2026 · prices as of October 8, 2026
| Company | Share of portfolio | Average buy price | Return | Current price | Last quarter |
|---|---|---|---|---|---|
| 54.5% | $136.69 | +37.6% | $188.12 | Added +381% | |
Insmed Inc.INSM | 17.9% | $78.31 | +28.3% | $100.48 | Reduced −62% |
| 12.1% | $119.14 | +28.0% | $152.52 | Added +0.6% | |
Abivax Sa-AdrABVX | 9.26% | $89.72 | −0.7% | $89.05 | Added +4.4% |
| 6.23% | $25.69 | +33.2% | $34.21 | Reduced −0.7% |
Darwin Global Management's buys and sells
| Company | Action | Shares change | Value now |
|---|---|---|---|
Ambrx Biopharma Inc.641871108 | New | +16,688,636 | $237.6M |
Ambrx Biopharma Inc.02290A102 | Sold out | −16,688,636 | — |
Immunovant Inc.IMVT | Sold out | −1,818,371 | — |
| New | +4,046,598 | $69.1M | |
| New | +1,039,289 | $62.8M | |
| New | +600,000 | $50.1M | |
| New | +1,060,427 | $42.2M | |
Vaxcyte Inc.PCVX | New | +579,959 | $36.4M |
Argenx SE - ADRARGX | Sold out | −45,615 | — |
Springworks Therapeutics Inc.85205L107 | New | +192,734 | $7M |
Nuvalent Inc.670703107 | New | +57,698 | $4.2M |
Darwin Global Management's portfolio by sector
Share of the stock portfolio at Q2 2026.
| Sector | Share |
|---|---|
| Health Care | 100% |
Portfolio performance: Darwin Global Management vs. benchmarks
Your result if you had bought each reported portfolio on the day it was made public and held it until the next report, against the S&P 500 and Nasdaq-100.
- You, copying after each 13F filing – estimated value
- S&P 500
- Nasdaq-100
| Total return | Per year | |
|---|---|---|
| You, copying after each 13F filing – estimated value | −35.0% | −8.2% |
| S&P 500 | +89.0% | +13.6% |
| Nasdaq-100 | +113.3% | +16.4% |
Prices were available for 64% of the portfolio value on average; the rest is left out of the return.
Darwin Global Management's most traded stocks
Quarters with a buy or a sell, all reports since Q4 2020.
| Company | Quarters bought | Quarters sold |
|---|---|---|
| 8 | 6 | |
Insmed Inc.INSM | 7 | 2 |
Vaxcyte Inc.PCVX | 3 | 2 |
| 2 | 3 | |
Argenx SE - ADRARGX | 1 | 4 |
| 2 | 3 | |
| 4 | 1 | |
| 2 | 3 | |
Abivax Sa-AdrABVX | 4 | 0 |
| 3 | 1 | |
Geron Corp.GERN | 1 | 3 |
| 2 | 2 | |
| 2 | 2 | |
Immunovant Inc.IMVT | 1 | 3 |
| 3 | 1 |